<?xml version="1.0" encoding="UTF-8"?>
<p>Infection with Zika virus (ZIKV) has traditionally been associated with asymptomatic or mild illness. Clinical manifestations, when they occur, include acute onset of fever, headache, maculopapular rash, arthralgias, myalgias, and/or non-purulent conjunctivitis [
 <xref rid="pntd.0004687.ref001" ref-type="bibr">1</xref>,
 <xref rid="pntd.0004687.ref002" ref-type="bibr">2</xref>]. In an outbreak in French Polynesia in 2013–14, there were, for the first time, reports of neurological and auto-immune complications, such as Guillain-Barré syndrome, in the setting of co-circulating dengue (DENV) and chikungunya (CHIKV) viruses [
 <xref rid="pntd.0004687.ref006" ref-type="bibr">6</xref>,
 <xref rid="pntd.0004687.ref007" ref-type="bibr">7</xref>]. With the progression of the Brazilian outbreak in 2015, the Brazilian Ministry of Health noted a striking concurrent increase in the number of infants born with microcephaly in areas with ZIKV transmission. Multiple subsequent studies have provided further documentation of the link between ZIKV and microcephaly and other birth defects, as well as with Guillain-Barré syndrome [
 <xref rid="pntd.0004687.ref008" ref-type="bibr">8</xref>–
 <xref rid="pntd.0004687.ref014" ref-type="bibr">14</xref>]. Based on the “strongly suspected” causal link between Zika virus and the observed fetal brain abnormalities, WHO has declared the current Zika epidemic a “public health emergency of international concern” [
 <xref rid="pntd.0004687.ref015" ref-type="bibr">15</xref>].
</p>
